Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Susanne, Herndlhofer"'
Autor:
Chantal Lucini, Klára Obrová, Isabella Krickl, Filomena Nogueira, Iva Kocmanová, Susanne Herndlhofer, Karoline V. Gleixner, Wolfgang R. Sperr, Tijana Frank, Nuno Andrade, Christina Peters, Gernot Engstler, Michael Dworzak, Andishe Attarbaschi, Martine van Grotel, Marry M. van den Heuvel-Eibrink, Ivan S Moiseev, Yuliya Rogacheva, Ludmilla Zubarovskaya, Natalia Zubarovskaya, Herbert Pichler, Anita Lawitschka, Elisabeth Koller, Felix Keil, Jiří Mayer, Barbora Weinbergerová, Peter Valent, Thomas Lion
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-6 (2024)
Abstract Invasive fungal disease (IFD) presents a life-threatening condition in immunocompromised patients, thus often prompting empirical administration of antifungal treatment, without adequate mycological evidence. Over the past years, wide use of
Externí odkaz:
https://doaj.org/article/c7e9e4e77a8c4a348f7597f39ffc6c98
Autor:
Irina Sadovnik, Daniel Ivanov, Dubravka Smiljkovic, Gabriele Stefanzl, Lina Degenfeld-Schonburg, Susanne Herndlhofer, Gregor Eisenwort, Alexander W. Hauswirth, Thamer Sliwa, Felix Keil, Wolfgang R. Sperr, Peter Valent
Publikováno v:
Cells, Vol 12, Iss 1, p 3 (2022)
Basophilia is a crucial prognostic variable in Ph-chromosome-positive chronic myeloid leukemia (CML). The ectoenzyme CD203c is an activation-linked surface antigen that is expressed specifically on basophil-committed progenitor cells and mature basop
Externí odkaz:
https://doaj.org/article/cf50c9f3426b423a9d5166447b5e48b9
Autor:
Mathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Chantal Blanche Lucini, Susanne Herndlhofer, Sandra Preuner, Klara Obrova, Petra Pusic, Nadine Witzeneder, Georg Greiner, Gregor Hoermann, Wolfgang R. Sperr, Thomas Lion, Michael Deininger, Peter Valent, Karoline V. Gleixner
Publikováno v:
EBioMedicine, Vol 50, Iss , Pp 111-121 (2019)
Purpose: Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1T315I-mutated cells in chronic myeloid leukemia (CML). However, due to side effects and resistance, BCR-ABL1T315I-mutated CML remains a clinical challenge. Hy
Externí odkaz:
https://doaj.org/article/fbb9dd16496d4e52a309a4b4f40496e3
Autor:
Katharina Blatt, Ingeborg Menzl, Gregor Eisenwort, Sabine Cerny-Reiterer, Harald Herrmann, Susanne Herndlhofer, Gabriele Stefanzl, Irina Sadovnik, Daniela Berger, Alexandra Keller, Alexander Hauswirth, Gregor Hoermann, Michael Willmann, Thomas Rülicke, Heinz Sill, Wolfgang R. Sperr, Christine Mannhalter, Junia V. Melo, Ulrich Jäger, Veronika Sexl, Peter Valent
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 6, Pp 632-642 (2018)
Leukemic stem cells (LSCs) are an emerging target of curative anti-leukemia therapy. In acute lymphoblastic leukemia (ALL), LSCs frequently express CD34 and often lack CD38. However, little is known about markers and targets expressed in ALL LSCs. We
Externí odkaz:
https://doaj.org/article/1452d10d7e4546a986e7d94a5ac51778
Autor:
Irene Graf, Georg Greiner, Rodrig Marculescu, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jäger, Alexander Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer‐Hohendanner, Peter Valent, Wolfgang R. Sperr
Publikováno v:
American Journal of Hematology. 98:290-299
Patient-related factors are of prognostic importance in acute myeloid leukemia (AML). Likewise, cardiac disorders may limit the tolerance of intensive therapy. Little is known about the prognostic value of N-terminal pro-brain natriuretic peptide (NT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6e9caa3553cb4d7af18ca87fda7a185
https://doi.org/10.1002/ajh.26805
https://doi.org/10.1002/ajh.26805
Autor:
Peter Valent, Thomas Rülicke, Matthias Mayerhofer, Wolfgang R. Sperr, Werner Rabitsch, Berthold Streubel, Susanne Herndlhofer, Irina Sadovnik, Sabine Cerny-Reiterer, Michael Willmann, Gregor Hoermann, Harald Herrmann, Katharina Blatt
PDF file - 162K, Supplementary Figure S1A: Expression of CD52 on CD34+/CD38+ cells in MDS and AML Supplementary Figure S1B: Expression of CD52 on CD34+/CD38+ cells in MDS, AML and control samples.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::614300ca9e003ec4eaf3e60657dde90e
https://doi.org/10.1158/1078-0432.22448322
https://doi.org/10.1158/1078-0432.22448322
Autor:
Peter Valent, Thomas Rülicke, Matthias Mayerhofer, Wolfgang R. Sperr, Werner Rabitsch, Berthold Streubel, Susanne Herndlhofer, Irina Sadovnik, Sabine Cerny-Reiterer, Michael Willmann, Gregor Hoermann, Harald Herrmann, Katharina Blatt
PDF file - 85K, Supplementary Table S1: Characteristics of patients with MDS Supplementary Table S2: Characteristics of patients with AML Supplementary Table S3: Characteristics of patients with CML, CMML, MPS, AUL, and ALL Supplementary Table S4: Ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abbc14d9bd431cb4b2cc6a98ae0c327a
https://doi.org/10.1158/1078-0432.22448301.v1
https://doi.org/10.1158/1078-0432.22448301.v1
Autor:
Peter Valent, Thomas Rülicke, Matthias Mayerhofer, Wolfgang R. Sperr, Werner Rabitsch, Berthold Streubel, Susanne Herndlhofer, Irina Sadovnik, Sabine Cerny-Reiterer, Michael Willmann, Gregor Hoermann, Harald Herrmann, Katharina Blatt
PDF file - 103K, Supplementary Figure S3: Expression of CD52 on CD34+/CD38− cells in different WHO subtypes of MDS and AML.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bcffe975595c7320f5084b8f7ab002d
https://doi.org/10.1158/1078-0432.22448316.v1
https://doi.org/10.1158/1078-0432.22448316.v1
Autor:
Peter Valent, Thomas Rülicke, Matthias Mayerhofer, Wolfgang R. Sperr, Werner Rabitsch, Berthold Streubel, Susanne Herndlhofer, Irina Sadovnik, Sabine Cerny-Reiterer, Michael Willmann, Gregor Hoermann, Harald Herrmann, Katharina Blatt
PDF file - 83K, Supplementary Table S6: Expression of CD52, CD123 and CLL-1 on CD34+/CD38−/CD90+/CD45RA− cells in patients with MDS and on CD34+/CD38−/CD90−/CD45RA− cells in patients with AML.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::546f2aa39671645cf3c237f3605943fc
https://doi.org/10.1158/1078-0432.22448310.v1
https://doi.org/10.1158/1078-0432.22448310.v1
Autor:
Peter Valent, Thomas Rülicke, Matthias Mayerhofer, Wolfgang R. Sperr, Werner Rabitsch, Berthold Streubel, Susanne Herndlhofer, Irina Sadovnik, Sabine Cerny-Reiterer, Michael Willmann, Gregor Hoermann, Harald Herrmann, Katharina Blatt
Purpose: The CD52-targeted antibody alemtuzumab induces major clinical responses in a group of patients with myelodysplastic syndromes (MDS). The mechanism underlying this drug effect remains unknown.Experimental Design: We asked whether neoplastic s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c540e73209dfc8550fff057054ad2d73
https://doi.org/10.1158/1078-0432.c.6521364.v1
https://doi.org/10.1158/1078-0432.c.6521364.v1